Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 8/20 | 0.59 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.56 |
| ▸ | INCENP | Q9NQS7 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 4/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 3/20 | 0.51 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.49 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15075236 | 0.91 | SYK (0.69) | SYKAURKBINCENPRAB9AMAPT | |
| SCHEMBL12409072 | 0.86 | SYK (0.67) | SYKAURKBINCENPEGFRERBB2 | |
| SCHEMBL27312847 | 0.85 | RAB9A (0.56) | SYKRAB9AMAPTL3MBTL1HPGD | |
| SCHEMBL17385133 | 0.85 | SYK (0.57) | SYKAURKBINCENPRAB9AMAPT | |
| SCHEMBL29989288 | 0.85 | SYK (0.57) | SYKAURKBINCENPRAB9AMAPT | |
| SCHEMBL2760114 | 0.84 | SYK (0.61) | SYKAURKBINCENPRAB9AMAPT | |
| SCHEMBL29568574 | 0.83 | SYK (0.58) | SYKAURKBINCENPMAPTHPGD | |
| SCHEMBL21340419 | 0.83 | SYK (0.58) | SYKAURKBINCENPMAPTHPGD | |
| SCHEMBL19089278 | 0.82 | SYK (0.67) | SYKAURKBINCENPMRGPRX4EGFR | |
| SCHEMBL12310935 | 0.82 | SYK (0.55) | SYKAURKBINCENPMAPTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024026056-A2 | HETEROARYL COMPOUNDS AS EGFR INHIBITORS AND THEIR USES | ACCUTAR BIOTECHNOLOGY, INC. (US) | 2024-02-01 | — | — | WO | disclosed |
| EP-3350181-B1 | HER3 LIGANDS AND USES THEREOF | UNIV CALIFORNIA (US) | 2023-11-01 | — | — | EP | disclosed |
| US-20230303523-A1 | METHOD FOR PREPARING PYROTINIB | SUZHOU FUSHILAI PHARMACEUTICAL CO., LTD (CN) | 2023-09-28 | — | — | US | disclosed |
| WO-2023141635-A2 | HER3 LIGANDS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-07-27 | — | — | WO | disclosed |
| WO-2021030711-A1 | ALKYNYL QUINAZOLINE COMPOUNDS | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2021-02-18 | — | — | WO | disclosed |
| EP-3778584-A1 | PRODUCTION PROCESS OF 2-CHLORO-4-HETEROARYL-PYRIMIDINE DERIVATIVES | ARIAD Pharmaceuticals, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| WO-2020215037-A1 | COMBINATION WITH CHECKPOINT INHIBITORS TO TREAT CANCER | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2020-10-22 | — | — | WO | disclosed |
| EP-3409669-B1 | HETEROARYL COMPOUNDS FOR KINASE INHIBITION | ARIAD PHARMA INC (US) | 2020-10-07 | — | — | EP | disclosed |
| US-10227342-B2 | Heteroaryl compounds for kinase inhibition | ARIAD PHARMACEUTICALS, INC. (US) | 2019-03-12 | — | — | US | disclosed |
| WO-2018098473-A1 | REAGENTS AND METHODS FOR ANALYSIS OF PROTEINS AND METABOLITES TARGETED BY COVALENT PROBES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-05-31 | — | — | WO | disclosed |
| US-20140303165-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. | 2014-10-09 | — | — | US | disclosed |
| US-8748606-B2 | 4,6-diaminopyrimidines useful as kinase inhibitors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2014-06-10 | — | — | US | disclosed |
| EP-1854789-B1 | QUINAZOLINE DERIVATIVE HAVING TYROSINE KINASE INHIBITORY ACTIVITY | SHIONOGI & CO (JP) | 2013-10-09 | — | — | EP | disclosed |
| US-20130217688-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2013-08-22 | — | — | US | disclosed |
| US-8445498-B2 | 4,6-disubstituted pyrimidines useful as kinase inhibitors | CELGENE AVILOMICS RESEARCH, INC. (US) | 2013-05-21 | — | — | US | disclosed |
| WO-2012122058-A2 | ALKYNE SUBSTITUTED QUINAZOLINE COMPOUND AND METHODS OF USE | NEWGEN THERAPEUTICS, INC. (US) | 2012-09-13 | — | — | WO | disclosed |
| US-8088766-B2 | Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors | ARRAY BIOPHARMA INC. (US) | 2012-01-03 | — | — | US | disclosed |
| WO-2011002523-A1 | PHOSPHORUS CONTAINING QUINAZOLINE COMPOUNDS AND METHODS OF USE | KANIONUSA INC. (US) | 2011-01-06 | — | — | WO | disclosed |
| WO-2010104406-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2010-09-16 | — | — | WO | disclosed |
| US-20090012290-A1 | CYANOGUANIDINES AND CYANOAMIDINES AS ERBB2 AND EGFR INHIBITORS | ARRAY BIOPHARMA, INC. (US) | 2009-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012290-A1 | CYANOGUANIDINES AND CYANOAMIDINES AS ERBB2 AND EGFR INHIBITORS | ERBB2, GRB2, EGFR | SYK 1967/4885AURKB 418/4885INCENP 3900/4885 |
| US-10227342-B2 | Heteroaryl compounds for kinase inhibition | ERBB2, EGFR, ERBB3 | SYK 408/4885AURKB 209/4885INCENP 4224/4885 |
| US-20130217688-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | SYK 2370/4885AURKB 1217/4885INCENP 3332/4885 |
| US-20140303165-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | SYK 2370/4885AURKB 1217/4885INCENP 3332/4885 |
| US-20230303523-A1 | METHOD FOR PREPARING PYROTINIB | JAK2, SRMS, JAK1 | SYK 24/4885AURKB 88/4885INCENP 3292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.